VIRINCHI · Virinchi Ltd · Software & Programming
VIRINCHI · Virinchi Ltd · Software & Programming
As of 06 Nov close
52-week range
51.5% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹70 Cr
Revenue YoY
PAT YoY
+11.6%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
0.5
P/S (TTM)
0.6
Sector P/E
64
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| VIRINCHI (this stock) | Not meaningful (earnings negative over the last 12 months) | 0.5 | -9.5% | -5.3% | 0.55 | 0.0% |
| Tata Consultancy Services | 15.6 | 7.6 | +18.1% | +48.0% | 8.93 | +2.9% |
| Infosys | 13.5 | 6.1 | +16.4% | +33.2% | 0.1 | +4.6% |
| HCL Technologies | 16.7 | 7.4 | +13.0% | +23.2% | 0.07 | +5.0% |
Promoter
stable
FII
falling 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedVirinchi Limited's FY2025-26 annual report highlights strategic focus on leveraging artificial intelligence across healthcare and fintech operations, with initiatives in personalized care, smarter credit decisions, and digital infrastructure. The report mentions a one-time write-off impacting consolidated results, though underlying businesses showed growth. The company emphasizes reimagining care and credit through technology, with plans for oncology expansion and AI integration.
- Strategic emphasis on AI integration across healthcare and fintech operations to drive personalized care and smarter credit decisions.
- Healthcare expansion initiatives including oncology block construction and digital empowerment through vHealth platform.
- Fintech focus on SaaS-based lending technology with US market expansion and AI-driven borrower assessment tools.
- Strengthening digital infrastructure and cybersecurity measures across IT services and fintech platforms.
- Corporate governance and stakeholder engagement with structured evaluation frameworks for board performance.
Key takeaway: Virinchi Limited is strategically reimagining care and credit through AI-driven solutions in healthcare and fintech, with a focus on digital infrastructure, personalized services, and corporate governance, despite challenges from geopolitical risks and cybersecurity threats.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (2 items); Default / Covenant Breach (3 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
2 occurrencesRecent (last 12 months)
NSE issued a warning letter to the company for not submitting the resignation letter of KMP within 7 days from the date of resignation.
Earlier (1-3 years ago)
Virinchi Limited was fined Rs.47,200 each by BSE and NSE for three instances of non-compliance with listing requirements related to equity share listings within 7 working days of approval for preferential issues. Additionally, NSE issued a warning letter for submitting a KMP resignation letter 1 day late.
Default / Covenant Breach
3 occurrencesRecent (last 12 months)
The company has undisputed statutory dues, including Provident Fund, Income-tax (TDS), and other material statutory dues, in arrears as of 31st March 2026 for more than 6 months from their due dates.
Earlier (1-3 years ago)
The company experienced a delay in payment of statutory dues, which contributed to a 691.32% variance in the Net Capital Turnover Ratio.
Older (3+ years ago)
Virinchi Limited had undisputed statutory dues, including Provident Fund, Income-Tax (TDS), and other material statutory dues, in arrears as at March 31, 2023 for a period of more than 6 months from the date they became payable.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has pending litigations disclosed as contingent liabilities in Note 39 of the standalone financial statements.
Earlier (1-3 years ago)
The company has a contingent liability of ₹30.11 crores from a corporate guarantee extended to its wholly owned subsidiary, M/s. Virinchi Healthcare Pvt Ltd, with an original amount of ₹39.84 crores.
Older (3+ years ago)
Virinchi Limited has pending litigations with liabilities disclosed as contingent liabilities, as mentioned in Note 36 of the Notes on accounts to the standalone financial statements.
Related-Party Transaction
3 occurrencesRecent (last 12 months)
The company has entered into transactions with related parties in compliance with the provisions of section 177 and 188 of the Act. The details of such related party transactions have been disclosed in the Note No.31 of the Standalone financial statements.
Earlier (1-3 years ago)
The company has disclosed multiple related-party transactions involving M/s. Virinchi Limited and M/s. Virinchi Healthcare Pvt Ltd with various entities, including loans, receivables, and advances, totaling over ₹1,400 Lacs.
Older (3+ years ago)
The company has entered into related-party transactions involving consultancy services, interest income, sale of software products, and housekeeping services with entities such as Tensor Fields Consultancy Services Private Limited, Virinchi Health Care Private Limited, and others.
Management & Board Governance
2 occurrencesRecent (last 12 months)
Mr. J. Suresh, an Independent Director, resigned from the company effective 1st June 2025, prior to the expiry of his term, citing personal reasons and confirming no other material issues.
Older (3+ years ago)
Sunder Kanaparthy, an Independent and Non-Executive director, resigned from the chairmanship of the Stakeholders Relationship Committee due to personal reasons, effective April 1, 2023. The board appointed Ms. Kunda Kalpana as the new chairman.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
9.23% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).